Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • ABBV-022
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • ABBV-022
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Codice etico e Modello 231

Philogen to join the Department of Radiology at Cambridge University (UK) for a lecture on June 22, 2022

Mar 15, 2022 | 2022, Events

Dario Neri, co-founder, CEO and CSO, is giving a lecture entitled “From encoded combinatorial libraries to clinical-stage radiopharmaceuticals”

Philogen to attend the Peptide Therapeutic Forum 2022 on August 25-26, 2022

Mar 15, 2022 | 2022, Events

Philogen announces its attendance at the Peptide Therapeutic Forum 2022. Samuele Cazzamalli, Head of Small Molecule Therapeutics at Philogen, is giving a lecture entitled “Small Molecule Therapeutics as an alternative to Peptide Therapeutics: a clean strategy to...

Philogen to attend the PEGS Europe 2022 on November 14-16, 2022

Mar 15, 2022 | 2022, Events

Dario Neri, co-founder, CEO and CSO, is giving a lecture entitled “Antibody-cytokine fusions: emerging clinical data in glioblastoma, sarcoma and dermato-oncology indications”. Dario Neri is giving a talk on “intra-cork” strategies to enhance the...

Philogen to participate at the Italian Top Picks Event organised by Stifel on January 17, 2022

Jan 5, 2022 | 2022, Past Events

Co-founder, CEO and CSO, Prof. Dario Neri and CFO Laura are giving a 1 hour presentation on January 17, 2022 at 16:00 CET.

Philogen to participate at the Italian Mid Cap Conference organised by Mediobanca on January 19-20, 2022

Jan 5, 2022 | 2022, Past Events

The Italian Midcap Conference provides an opportunity for investors to get a perspective of Philogen progresses and to meet CEO Dario Neri  and CFO Laura Baldi through a series of one-on-one meetings. Mediobanca Italian Mid Cap Conference 

Recent Posts

  • 23 maggio 2022 – Aggiornamento sul programma di acquisto di azioni proprie
  • Deposito del Verbale dell’Assemblea degli Azionisti
  • 16 maggio 2022 – Aggiornamento sul programma di acquisto di azioni proprie
  • The Board of Directors approves the net financial position for the first quarter of 2022
  • Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al primo trimestre 2022

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it